Satralizumab, previously known as SA-237 , represents a significant option for NMOSD and other autoimmune ailments. Emerging clinical trials have demonstrated favorable results regarding its action in reducing relapses and disease progression . In particular , Phase III examinations – including the ADAPT study – have evaluated the effect of Sa

Recent data suggests that Cilgavimab, formerly known as COV2-2130, presents significant potential as a clinical agent in combating COVID-19. This protein exhibits a distinctive mechanism of action , specifically targeting the pathogen's ACE2 receptor binding domain with considerable strength . Initial trials indicate a robust capacity to block infe